{"doi":"10.3390/vaccines10020191","title":"Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study","abstract":"<jats:p>The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (&lt;30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.</jats:p>","journal":"Vaccines","year":2022,"id":637026,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1225278,"name":"Duaa W. Al‐Sadeq","orcid":"0000-0002-0487-3365","position":1,"is_corresponding":false},{"id":1653780,"name":"Haissam Abou-Saleh","orcid":"0000-0003-3460-1413","position":2,"is_corresponding":false},{"id":1653782,"name":"Nader Al-Dewik","orcid":"0000-0001-5739-1135","position":3,"is_corresponding":false},{"id":1653783,"name":"Amira E. Elsharafi","orcid":"0000-0003-4523-2748","position":4,"is_corresponding":false},{"id":1653784,"name":"Fatima M. Hamaydeh","orcid":null,"position":5,"is_corresponding":false},{"id":1653786,"name":"Bushra Y. Abo Halawa","orcid":"0000-0002-8758-3303","position":6,"is_corresponding":false},{"id":1653787,"name":"Tala M. Jamaleddin","orcid":"0000-0002-9272-1168","position":7,"is_corresponding":false},{"id":1653790,"name":"Huda M. Abdul Hameed","orcid":null,"position":8,"is_corresponding":false},{"id":1653792,"name":"Parveen B. Nizamuddin","orcid":null,"position":9,"is_corresponding":false},{"id":1653796,"name":"Fathima Humaira Amanullah","orcid":null,"position":10,"is_corresponding":false},{"id":1653798,"name":"Hanin I. Daas","orcid":"0000-0001-9074-2726","position":11,"is_corresponding":false},{"id":48791,"name":"Laith J. Abu‐Raddad","orcid":"0000-0003-0790-0506","position":12,"is_corresponding":false},{"id":1225286,"name":"Gheyath K. Nasrallah","orcid":"0000-0001-9252-1038","position":13,"is_corresponding":false},{"id":1276836,"name":"Farah M. Shurrab","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study","abstract":"<jats:p>The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (&lt;30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.</jats:p>","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35214650","pmcid":"PMC8877530","openalex_id":"https://openalex.org/W4210803241","authors":[],"funders":[{"funder_name":"Qatar National Research Fund","grant_id":"UREP28-173-3-07","title":null}],"total_grants":1,"fwci":0.2898,"citation_percentile":0.51590632,"influential_citations":0,"citation_trend":[{"year":2022,"count":2},{"year":2025,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2076-393X/10/2/191/pdf?version=1643279955","host_type":"journal"},{"url":"https://www.mdpi.com/2076-393X/10/2/191/pdf?version=1643279955","host_type":"publisher"},{"url":"https://www.mdpi.com/2076-393X/10/2/191/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/vaccines10020191","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35214650","host_type":"repository"},{"url":"https://doaj.org/article/dd53fde9049c4b0fb45831c6d3e21bd8","host_type":"repository"},{"url":"https://figshare.com/articles/journal_contribution/Assessment_of_the_Neutralizing_Antibody_Response_of_BNT162b2_and_mRNA-1273_SARS-CoV-2_Vaccines_in_Na_ve_and_Previously_Infected_Individuals_A_Comparative_Study/25539625","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8877530","host_type":"repository"},{"url":"https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85124042840&origin=inward","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8877530","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8877530?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","Animal Virus Infections Studies","Viral gastroenteritis research and epidemiology"],"mesh_terms":[],"keywords":["Neutralizing antibody","Coronavirus disease 2019 (COVID-19)","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Vaccination","Messenger RNA","Antibody response","Medicine","Antibody","Immune system","2019-20 coronavirus outbreak","Virology","Immunology","Internal medicine","Gene","Biology","Disease","Outbreak","Infectious disease (medical specialty)","Vaccine","Neutralizing Antibodies","Sars-cov-2","Moderna-mrna-1273","Pfizer-bnt162b2"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T18:10:44.448318Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}